Skip to Content
Merck
All Photos(1)

Key Documents

Y0001306

Cefpodoxime proxetil for peak identification

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

Cefpodoxime proxetil

Sign Into View Organizational & Contract Pricing

Select a Size

10 MG
€107.00

€107.00

Please contact Customer Service for Availability
Request a Bulk Order
All Photos(1)

Select a Size

Change View
10 MG
€107.00

About This Item

Empirical Formula (Hill Notation):
C21H27N5O9S2
CAS Number:
87239-81-4
Molecular Weight:
557.60
UNSPSC Code:
41116107
NACRES:
NA.24

€107.00

Please contact Customer Service for Availability
Request a Bulk Order

grade

pharmaceutical primary standard

API family

cefpodoxime

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

−20°C

SMILES string

[s]1c(nc(c1)\C(=N\OC)\C(=O)N[C@H]2[C@H]3SCC(=C(N3C2=O)C(=O)OC(OC(=O)OC(C)C)C)COC)N

InChI

1S/C21H27N5O9S2/c1-9(2)33-21(30)35-10(3)34-19(29)15-11(6-31-4)7-36-18-14(17(28)26(15)18)24-16(27)13(25-32-5)12-8-37-20(22)23-12/h8-10,14,18H,6-7H2,1-5H3,(H2,22,23)(H,24,27)/b25-13-/t10?,14-,18-/m1/s1

InChI key

LTINZAODLRIQIX-FBXRGJNPSA-N

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Cefpodoxime proxetil for peak identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Vasu Kumar Kakumanu et al.
Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 128(3), 439-445 (2008-03-04)
Cefpodoxime proxetil (CP) is a prodrug with poor oral bioavailability because of its metabolism to Cefpodoxime acid (CA) in luminal contents and intestinal epithelial cells. In the present investigation, regional variability in different segments of the gastrointestinal tract vis-à-vis solubility
Naoto Fukutsu et al.
Chemical & pharmaceutical bulletin, 54(10), 1469-1472 (2006-10-04)
Cross-contamination is a critical issue for pharmaceutical manufacturing, especially for beta-lactam antibiotics. Thus, an analytical method for the simultaneous determination of beta-lactam antibiotics cefmetazole (CMZ) and cefpodoxime proxetil (CPDXPR) contaminants in non-beta-lactam pharmaceuticals was developed using high-performance liquid chromatography-tandem mass
Momin A Mujeeb et al.
Indian journal of medical sciences, 65(2), 43-49 (2011-02-01)
Cefpodoxime is a semisynthetic third generation cephalosporin analogue with a relatively broader spectrum of antimicrobial activity against gram negative and gram positive organisms. This is attributed to their somewhat increased resistance to degradation by the betalactamase. Cefpodoxime shows good activity
Vasu Kumar Kakumanu et al.
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 64(2), 255-259 (2006-06-27)
Cefpodoxime proxetil (CP) is a prodrug of cefpodoxime acid (CA), and is supplied as racemic mixture of R- and S-enantiomers. CP has only 50% absolute bioavailability, and the reasons responsible for low bioavailability remain poorly understood. The present work ascertains
Hakki Yilmaz et al.
Current drug safety, 8(2), 145-147 (2013-07-13)
We report a case of acute interstitial nephritis (AIN) and immune hemolytic anemia (IHA) associated with cefpodoxime therapy. A patient with a recent history of cefpodoxime proxetil treatment presented with elevated serum creatinine, oliguria, nausea, vomiting, and dyspnea. Evidence of
View All Related Papers

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service